[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastroesophageal-adenocarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastroesophageal-adenocarcinoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,51,93,126,157,179,220,245,273,301,324,359,381,401,423,447,469,489],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100606496","phase-2-zanidatamab-in-combination-with-pembrolizumab-and-chemotherapy-in-her2-and-pd-l1-positive-metastatic-gastroesophageal-adenocarcinoma-gea-patients-100606496",false,"NCT07176312","Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients","- ZANGEA - Phase II Study of Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients","ZANGEA","Inclusion Criteria:\n\n* Patient\\* has signed and dated a written informed consent form in accordance with regulatory and institutional guidelines and approved by an institutional Review Board \u002F Independent Ethics Committee. This must be obtained before the performance of any protocol-related procedures that are not part of normal subject care.\n* Patient is, in the investigator's judgement, willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study.\n* Patient is ≥ 18 years of age at time of signing the written informed consent.\n* Patient has been diagnosed with histologically confirmed unresectable advanced\u002Fmetastatic HER2-positive (defined as IHC 3+ or IHC 2+ with ISH+) and PD-L1-positive (combined positive score CPS ≥ 1) gastroesophageal adenocarcinoma per local standard assessment of new or archival tumor tissue. Results of local HER2 and PD-L1 assessment will be retrospectively confirmed by central pathological re-assessment.\n\nNote: In case of metachronous metastases, particularly in case of prior treatment with PD-(L)1-antibodies, a fresh re-biopsy should be performed for immunohistochemistry testing (local pathology), if feasible.\n\n* Patient has assessable disease (measurable or non-measurable) per RECIST v1.1.\n* Patient did not receive previous palliative treatment. Prior adjuvant or neoadjuvant chemotherapy, immunotherapy, radiotherapy and\u002For chemoradiotherapy (but not anti HER2-targeted treatment) are permitted as long as the last administration of the last regimen (whichever was given last) occurred at least 6 months prior to enrolment.\n* Patient has ECOG performance status ≤ 1.\n* Patient has adequate hepatic, renal and hematologic functions:\n\n  1. Absolute number of neutrophils (ANC) ≥ 1.5 x 10\\^9\u002FL\n  2. Platelets ≥ 100x10\\^3\u002FµL\n  3. Serum creatinine ≤ 1.5 x ULN or creatinine clearance (measured by 24 h urine) ≥ 30 mL\u002Fmin (i.e., if serum creatinine level is \\> 1.5 x upper limit of normal (ULN), then a 24-hour urine test must be performed to check the creatinine clearance to be determined.\n  4. AST (SGOT) and ALT (SGPT) ≤ 3.0 x ULN (or ≤ 5.0 x ULN if liver metastases are present)\n  5. Total Bilirubin ≤ 1.5 x ULN (or \\\u003C 3.0 x ULN in case of prior liver involvement or Gilbert's Syndrome)\n* Patient has adequate coagulation function as defined by International Normalized Ratio (INR) ≤ 1.5, and a partial thromboplastin time (PTT) ≤ 5 seconds above the ULN (unless receiving anticoagulation therapy).\n* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of human chorionic gonadotrophin \\[hCG\\]) within 7 days prior to the start of study drug. Women must not be breastfeeding. WOCBP must use a highly effective method(s) of contraception during the treatment period and for 4 months after last dose of zanidatamab and\u002For pembrolizumab, or 6 months after the last dose of chemotherapy, whichever occurs last. Males who are sexually active with WOCBP must agree to remain abstinent or follow instructions for method(s) of contraception during the treatment and for 4 months after the last dose of zanidatamab and\u002For pembrolizumab, or 6 months after the last dose of chemotherapy, whichever occurs last. In addition, male subjects must be willing to refrain from sperm donation during this time.\n\n  * There are no data that indicate special gender distribution. Therefore, patients will be enrolled in the study gender-independently.\n\nExclusion Criteria:\n\n* Patient has any known contraindication including allergy or hypersensitivity to the trial drugs or any constituent of the products as well as a known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies.\n* Patient received prior anti HER2-targeted treatment for GEA.\n* Patient has malignancies other than the disease under study within 5 years prior to inclusion, except for those with a negligible risk of metastasis or death (e.g., expected 5-year OS \\> 90%) treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent).\n* Patient has untreated known CNS metastases. Patient is eligible, if previous CNS metastases are adequately treated and patient has neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for ≥ 2 weeks prior to enrolment, and did not receive corticosteroids, or is on a stable or decreasing dose of \\\u003C 10 mg daily prednisone (or equivalent) for ≥ 2 weeks prior to inclusion.\n* Patient has abnormal baseline left ventricular ejection fraction (LVEF \\\u003C 50 %), assessed by echocardiogram, multigated acquisition (MUGA) scan, or cardiac magnetic resonance imaging (MRI) scan.\n* Patient has active, known, or suspected autoimmune disease. Exception: Type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, or skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll. For any cases of uncertainty, it is recommended that the medical expert\u002Fsponsor be consulted prior to signing informed consent.\n* Patient has a condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of trial drug administration. Inhaled or topical steroids, and adrenal replacement doses \\> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.\n* Patient has persisting toxicity related to prior therapy (NCI CTCAE v.5.0 Grade \\> 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on investigator's judgment are acceptable.\n* Patient has any serious or uncontrolled medical disorder or active infection that, in the opinion of the investigator, may increase the risk associated with trial participation, trial drug administration, or would impair the ability of the patient to receive trial drug.\n* Patient has significant acute or chronic infections including, among others:\n* Any positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).\n* Any positive test result for hepatitis B virus or hepatitis C virus indicating acute or chronic infection.\n* Patient has history of allogeneic tissue \u002F solid organ transplant.\n* Patient has been incarcerated or involuntarily institutionalized by court order or by the authorities \\[§ 40 Abs. 1 S. 3 Nr. 4 AMG\\].\n* Patient is unable to consent because he\u002Fshe does not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts \\[§ 40 Abs. 1 S. 3 Nr. 3a AMG\\].\n* Patient has evidence of any other disease, neurologic or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of any of the trial medications, puts the patient at higher risk for treatment-related complications or may affect the interpretation of trial results.\n* Patient currently participates in any other interventional clinical study within 30 days before the first administration of the investigational product or at any time during the trial, unless it is an observational (non-interventional) study, or during the follow-up period of an interventional study with last dose of investigational product ≥28 days prior to enrolment in this trial.\n* Patient has a known complete absence of dihydropyrimidine dehydrogenase (DPD) activity or use of any medications known to inhibit DPD (including brivudine, sorivudine and analogs) within 4 weeks prior to enrolment.\n* Female patients, who are pregnant or breast feeding or planning to become pregnant within and 6 months after the end of treatment. Female patients of childbearing potential must have a negative serum pregnancy test result within 7 days prior to initiation of trial treatment.","ALL","18 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The ZANGEA trial is a open-label, single arm, multicenter phase II trial assessing the efficacy of zanidatamab in combination with pembrolizumab and chemotherapy in patients with metastatic gastroesophageal adenocarcinoma (GEA). The patients need to be previously untreated in the palliative setting and tested positive for HER2 and PD-L1.",[27,28,29,30,31],"Gastroesophageal Adenocarcinoma","First Line Therapy","HER2 + Gastric Cancer","PDL-1","Metastases",[33,34,35,36,37],"GEA","Gastroesophageal adenocarcinoma","first line therapy","HER2-positive","PD-L1 positive","RECRUITING","2026-06-29",{"date":41,"type":42},"2026-06-30","ACTUAL",{"date":44,"type":42},"2026-01-16",{"date":46,"type":21},"2029-03",{"name":48,"class":49},"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","OTHER",20,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":73,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100614693","phase-2-trial-comparing-standard-of-care-therapy-with-and-without-sequential-cytoreductive-intervention-for-patients-with-metastatic-foregut-adenocarcinoma-and-undetectable-circulating-tumor-deoxyribose-nucleic-acid-ctdna-levels-100614693","NCT07282912","Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels","Phase II Prospective, Open Label Randomized Controlled Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels","OLIGOMETS","Inclusion Criteria:\n\n* Has a primary diagnosis of AJCC 8th Edition Stage IV esophageal or gastroesophageal adenocarcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder adenocarcinoma, duodenal, and ampullary adenocarcinoma.\n\n  a) All participants must have confirmed histologic diagnosis of the primary tumor, which may be confirmed retrospectively by a radiologist if necessary.\n* Has a primary tumor that must be locally resectable or can be treated definitively. Primary tumors included are esophageal, gastric, duodenal, ampullary, pancreatic, cholangiocarcinoma, and gall bladder carcinoma. Primary tumors should be resectable or treatable with consolidative radiotherapy or ablative therapy such as microwave ablation or trans-arterial chemo\u002Fradioembolization (cholangiocarcinomas).\n* Has limited (2 sites) metastatic disease determined to be completely resectable or treatable with curative intention (see SOE) at the time of diagnosis. This includes:\n\n  1. Up to five pulmonary metastases amenable to wedge resection (maximum of three wedge resections) or lobectomy (single lobectomy) or consolidative radiation\u002Fablative therapy\n  2. Up to five hepatic metastases amenable to hepatectomy (segmentectomy, sectionectomy, sectorectomy, minor hepatectomy, not more than three segments), wedge resection requiring a minimum of 40% of liver parenchyma following resection based on future liver remnant or a combination of partial hepatectomy and microwave ablation or trans-arterial radioembolization (TARE).\n  3. Lymphatic metastases that are resectable or intervenable (limited to only two non-regional sites) (see Appendix 3).\n  4. Resectable peritoneal disease with a PCI of ≤6 and the ability to obtain a CC0 cytoreduction.\n  5. Distant metastasis must be limited to two of the above-mentioned sites (a-d).\n  6. If both pulmonary and liver metastasis are present (a, b), then a total of five lesions will be considered oligometastatic.\n* Patients with resected primary tumors can be included if they present with oligometastases at least six months after the completion of treatment of primary tumor with curative intent.\n* Has adequate organ function, as described below (see Appendix 4); all screening laboratory tests should be performed within 30 days prior to the first study intervention.\n* Patients must have had two concordant negative tissue informed ctDNA tests measured at different timepoints and with the second being within 45 days prior to enrollment.\n* Patients must have at least 4 months of prior effective systemic therapy.\n* Has hemoglobin ≥ 8 g\u002FdL.\n* Has ANC ≥ 1500\u002FuL.\n* Has platelet count ≥ 75000\u002FuL.\n* Has total bilirubin ≤ 1.5 times the upper limit of normal (ULN).\n* Has aspartate aminotransferase (AST) \\& alanine aminotransferase (ALT) ≤ 5 times ULN.\n* Has creatinine clearance ≥ 50 mL\u002Fmin.\n* Patient who is at least 18 years of age at the time of signing informed consent and less than 81 years of age at the time of signing informed consent.\n* Has an ECOG performance status score 0-1 (see Appendix 6) at the time of randomization.\n* A male participant must agree to use contraception (barrier birth control, abstinence) during the treatment period and for at least 95 days following completion, corresponding to time needed to eliminate any study intervention(s), and refrain from donating sperm during this period.\n* A female participant of childbearing age is eligible to participate if she is not pregnant, not breastfeeding, and agrees to use contraception (hormonal, barrier birth control, or abstinence) during the treatment period and for at least 95 days following completion. Should a woman become pregnant or suspect that she is pregnant while participating in this study, she should inform her treating physician immediately.\n\nInformed Consent\n\n* The participant (or legally acceptable representative if applicable) provides written informed consent for the study. The participant may also provide consent for the Foundation for Blood Research (FBR). However, the participant may participate in the main study without participating in the FBR.\n\nExclusion Criteria:\n\n* Has a positive urine pregnancy test within 3 days prior to randomization or treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\nNote: In the event that 3 days have elapsed between the screening pregnancy test and the first dose of study intervention, another pregnancy test (urine or serum) must be performed and must be negative for the participant to start receiving study medication.\n\n* Has hypoxia as defined by pulse oximeter reading \\\u003C92% at rest or requires intermittent or chronic supplemental oxygen.\n* Has developed progressive disease on current line of systemic therapy.\n* Has a known additional malignancy that is progressing or has required active treatment within the past three years.\n\nNote: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.\n\n* Has known CNS metastasis and\u002For carcinomatous meningitis.\n* Has known osseous metastasis.\n* Has clinically significant cardiac disease, including unstable angina, acute myocardial infarction within 6 months from treatment initiation, or New York Heart Association Class III or IV congestive heart failure. Medially controlled arrhythmia stable on medication is permitted.\n* Has poorly controlled hypertension defined as SBP ≥150mmHg and\u002For DBP ≥90mmHg.\n* Has moderate to severe hepatic impairment (Child-Pugh B or C).\n* Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study.\n* Is unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption (severe dysphasia, bowel obstruction, malabsorption).\n* Has known malignant pleural effusion or previous malignant effusion previously treated at the time of enrollment.\n* Has histologic subtypes not included in the inclusion criteria (including esophageal squamous cell carcinoma, gastroenteropancreatic neuroendocrine tumors, hepatocellular carcinoma, etc.).\n* Has a primary tumor that is not amenable to the treatment modalities listed in section 3.\n* Has albumin level less than 3.0 g\u002FdL despite appropriate nutritional support. Diagnostic Assessments\n* Has detectable ctDNA at the time of enrollment.\n* Has an active infection requiring systemic therapy.\n* Has known active TB\u002FCOVID infection.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (dosing exceeding 10mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of the study intervention.\n* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 95 days after the last study intervention.\n* Inability to receive chemotherapy and\u002For surgery and\u002For radiotherapy and\u002For ablative procedures due to medical\u002Finsurance reasons.\n* Requires emergency surgery due to bleeding, perforation, or obstruction.","80 Years",{"count":61,"type":21},54,[24],"This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy for patients with intervenable oligometastatic (stage IV) cancer of the upper gastrointestinal (GI) tract and undetectable ctDNA at the time of randomization after a three-month induction chemotherapy period.",[65,66,27,67,68,69,70,71,72],"Foregut Adenocarcinoma","Esophageal Adenocarcinoma","Gastric Adenocarcinoma","Pancreas Adenocarcinoma","Duodenal Adenocarcinoma","Ampullary Adenocarcinoma","Gallbladder Adenocarcinoma","Intra - and Extrahepatic Cholangiocarcinoma",[74,75,76,77,78,79,80,81,82],"Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels","Oligometastasis","Esophageal adenocarcinoma","Gastroesophageal adenocarcinoma,","Gastric adenocarcinoma","Duodenal adenocarcinoma","Pancreatic\u002Fampullary adenocarcinoma","Gallbladder adenocarcinoma","Intra- and extrahepatic cholangiocarcinoma.","2026-06-17",{"date":85,"type":42},"2026-06-22",{"date":87,"type":42},"2026-06-02",{"date":89,"type":21},"2028-06",{"name":91,"class":49},"Yale University",1,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":104,"conditions":105,"keywords":109,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":92},"100556800","phase-1-personalized-cancer-vaccine-pcv-strategy-in-patients-with-solid-tumors-and-molecular-residual-disease-100556800","NCT06529822","Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease","Phase 1 Clinical Trial of a Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease","Inclusion Criteria Cohort #1:\n\n* Age ≥ 18 years.\n* ECOG performance status ≤ 2 (Karnofsky ≥ 60%).\n* Histologically confirmed muscle-invasive bladder cancer (MIBC) or upper tract urothelial carcinoma (renal pelvis and\u002For ureter).\n* Patients with carcinomas showing mixed histologies are required to have a dominant transitional cell pattern.\n* Complete surgical resection of MIBC (R0) or upper tract urothelial carcinoma (renal pelvis and\u002For ureter). Tumor, nodes, metastases (TNM) classification (based on the American Joint Committee on Cancer (AJCC) Cancer Staging Manual 8th ed.) at pathological examination of surgical resection specimen as follows: pT2-4aN0M0 or pT0-4aN+M0.\n* Patient must have fully recovered from surgical resection in the opinion of the treating MD.\n* ctDNA positive result as identified by Signatera.\n* Radiologic confirmation (by conventional imaging) of absence of residual disease and absence of metastasis.\n* Adequate bone marrow and organ function as defined below:\n\n  * WBC ≥ 1.5 K\u002Fcumm\n  * Absolute neutrophil count ≥ 1.0 K\u002Fcumm\n  * Platelets ≥ 50 K\u002Fcumm\n  * Hemoglobin ≥ 8.0 g\u002FdL\n  * Total bilirubin ≤ 1.5 x IULN\n  * AST(SGOT)\u002FALT(SGPT) ≤ 3.0 x IULN\n  * Creatinine clearance \\> 30 mL\u002Fmin by Cockcroft-Gault\n* The effects of synthetic long peptide personalized cancer vaccines and Hiltonol on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 5 months after completion of study interventions. Should a woman become pregnant or suspect she is pregnant while participating in this study or should a man suspect he has fathered a child, s\u002Fhe must inform her treating physician immediately.\n* No concurrent investigational therapies outside of this protocol are allowed.\n* Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria Cohort #1:\n\n* Receiving any other investigational agents, or planning to receive other investigational agents as part of neoadjuvant therapy. Patients who have received perioperative neoadjuvant chemotherapy and immunotherapy are allowed.\n* Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty.\n* A psychiatric illness or social situations that would limit compliance with study requirements as determined by the investigator from the medical history, physical exam, and\u002For medical record.\n* Prior or currently active autoimmune disease requiring management with immunosuppression. This includes inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemia, immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, sarcoidosis, or other rheumatologic disease or any other medical condition or use of medication (e.g., corticosteroids) which might make it difficult for the patient to complete the full course of treatments or to generate an immune response to vaccines. In the case of asthma or chronic obstructive pulmonary disease taking inhaled corticosteroids that does not require daily systemic corticosteroids is acceptable. Additionally, local acting steroids (topical, inhaled, or intraarticular) will be allowed. Patients on intermittent or short course steroids will be allow if the dose does not exceed 4 mg of dexamethasone (or equivalent) per day for \\> 7 consecutive days. Premedication for chemotherapy does not apply to this criterion and may be administered as per SOC practice. Any patients receiving steroids should be discussed with the PI to determine if eligible.\n* Known HIV-positive status.\n* History of positive test for Hepatitis B virus surface antigen (HBsAg) and\u002For positive Hepatitis C antibody result with detectable hepatitis C virus (HCV) ribonucleic acid (RNA) indicating acute or chronic infection\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> Grade 1) with the exception of alopecia. For treatment enrollment the patient must have completed all prior cancer treatments \\> 28 days prior to vaccine administration with the exception of adjuvant SOC immunotherapy.\n* Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial per discussion with the PI.\n* Currently receiving any other investigational agents.\n* Live vaccine administered within 30 days prior to enrollment.\n* Immunodeficiency, systemic steroid therapy, or any other immunosuppressive therapy within 30 days of enrollment.\n* Active autoimmune disease (excluding diabetes mellitus and\u002For vitiligo), solid organ or allogeneic bone marrow transplant, or other known contraindications to receiving immunotherapy.\n* Severe hypersensitivity (grade ≥ 3) to checkpoint inhibitors and\u002For any of its excipients.\n* Current pneumonitis, a history of (non-infectious) pneumonitis requiring steroids, or history of clinically significant interstitial lung disease.\n* Active tuberculosis test within 3 months prior to treatment initiation.\n* Pregnant and\u002For breastfeeding. Women of childbearing potential must have a negative serum\u002Furine pregnancy test within 7 days of study entry.\n\nInclusion Criteria Cohort #2:\n\n* Age ≥ 18 years.\n* ECOG performance status ≤ 2 (Karnofsky ≥ 60%)\n* Histologically confirmed gastroesophageal adenocarcinoma\n* Stage II or III gastroesophageal adenocarcinoma (GEC).\n* Complete surgical resection of GEC (R0). Full recovery from surgery and enrollment within 52 weeks following surgery with curative intent. Tumor, nodes, metastases (TNM) classification (based on the American Joint Committee on Cancer (AJCC) Cancer Staging Manual 8th ed.) at pathological examination of surgical resection specimen as follows:\n\n  * Esophageal and Esophagogastric junction adenocarcinoma T1 N1-3 M0 or T2-4 N0-2M0.\n  * Gastric adenocarcinoma T1-2 N1-3 M0 or T3-4 N0-3 M0.\n* Patient must have fully recovered from surgical resection in the opinion of the treating MD.\n* ctDNA positive result as identified by Signatera.\n* Radiologic confirmation (by conventional imaging) of absence of residual disease and absence of metastasis.\n* Adequate bone marrow and organ function as defined below:\n\n  * WBC ≥ 1.5 K\u002Fcumm\n  * Absolute neutrophil count ≥ 1.0 K\u002Fcumm\n  * Platelets ≥ 50 K\u002Fcumm\n  * Hemoglobin ≥ 8.0 g\u002FdL\n  * Total bilirubin ≤ 1.5 x IULN\n  * AST(SGOT)\u002FALT(SGPT) ≤ 3.0 x IULN\n  * Creatinine clearance \\> 30 mL\u002Fmin by Cockcroft-Gault\n* The effects of synthetic long peptide personalized cancer vaccines and Hiltonol and on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 5 months after completion of study interventions. Should a woman become pregnant or suspect she is pregnant while participating in this study or should a man suspect he has fathered a child, s\u002Fhe must inform her treating physician immediately.\n* No concurrent investigational therapies outside of this protocol are allowed.\n* Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria Cohort #2:\n\n* Receiving any other investigational agents or planning to receive other investigational agents as part of neoadjuvant therapy. Patients who have received perioperative neoadjuvant chemotherapy and immunotherapy are allowed.\n* Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty.\n* A psychiatric illness or social situations that would limit compliance with study requirements as determined by the investigator from the medical history, physical exam, and\u002For medical record.\n* Prior or currently active autoimmune disease requiring management with immunosuppression. This includes inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemia, immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, sarcoidosis, or other rheumatologic disease or any other medical condition or use of medication (e.g., corticosteroids) which might make it difficult for the patient to complete the full course of treatments or to generate an immune response to vaccines. In the case of asthma or chronic obstructive pulmonary disease taking inhaled corticosteroids that does not require daily systemic corticosteroids is acceptable. Additionally, local acting steroids (topical, inhaled, or intraarticular) will be allowed. Patients on intermittent or short course steroids will be allow if the dose does not exceed 4 mg of dexamethasone (or equivalent) per day for \\> 7 consecutive days. Premedication for chemotherapy does not apply to this criterion and may be administered as per SOC practice. Any patients receiving steroids should be discussed with the PI to determine if eligible.\n* Known HIV-positive status.\n* History of positive test for Hepatitis B virus surface antigen (HBsAg) and\u002For positive Hepatitis C antibody result with detectable hepatitis C virus (HCV) ribonucleic acid (RNA) indicating acute or chronic infection.\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> Grade 1) with the exception of alopecia. For treatment enrollment the patient must have completed all prior cancer treatments \\> 28 days prior to vaccine administration with the exception of adjuvant SOC immunotherapy.\n* Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial per discussion with the PI.\n* Currently receiving any other investigational agents.\n* Live vaccine administered within 30 days prior to enrollment.\n* Immunodeficiency, systemic steroid therapy, or any other immunosuppressive therapy within 30 days of enrollment.\n* Active autoimmune disease (excluding diabetes mellitus and\u002For vitiligo), solid organ or allogeneic bone marrow transplant, or other known contraindications to receiving immunotherapy.\n* Severe hypersensitivity (grade ≥ 3) to checkpoint inhibitors and\u002For any of its excipients.\n* Current pneumonitis, a history of (non-infectious) pneumonitis requiring steroids, or history of clinically significant interstitial lung disease.\n* Active tuberculosis test within 3 months prior to treatment initiation.\n* Pregnant and\u002For breastfeeding. Women of childbearing potential must have a negative serum\u002Furine pregnancy test within 14 days of study entry.\n\nInclusion Criteria Cohort #3:\n\n* Age ≥ 18 years.\n* ECOG performance status ≤ 1.\n* Histologically or cytologically confirmed diagnosis of Melanoma. Stage IIB\u002FC or IIIB-C (per AJCC 8th edition). Completed R0 resection within 36 months prior to enrollment and have fully recovered from surgery.\n* Planning to receive or have received adjuvant immunotherapy for 1 year.\n* Availability of a SignateraTM ctDNA report within 28 days prior to enrollment demonstrating ctDNA-positivity (MRD+). Note: Patients may be pre-screened prior to obtaining ctDNA results to facilitate assay design.\n* Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n* Radiologic confirmation (by conventional imaging) of absence of residual disease and absence of metastasis.\n* Adequate bone marrow and organ function as defined below:\n\n  * WBC ≥ 1.5 K\u002Fcumm\n  * Absolute neutrophil count ≥ 1.0 K\u002Fcumm\n  * Platelets ≥ 50 K\u002Fcumm\n  * Hemoglobin ≥ 8.0 g\u002FdL\n  * Total bilirubin ≤ 1.5 x IULN\n  * AST(SGOT)\u002FALT(SGPT) ≤ 3.0 x IULN\n  * Creatinine clearance \\> 30 mL\u002Fmin by Cockcroft-Gault\n* Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria Cohort #3:\n\n* Receiving any other investigational agents or planning to receive other investigational agents in the neoadjuvant or adjuvant setting.\n* Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty.\n* A psychiatric illness or social situation that would limit compliance with study requirements as determined by the investigator from the medical history, physical exam, and\u002For medical record.\n* Prior or currently active autoimmune disease requiring management with immunosuppression. This includes inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemia, immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, sarcoidosis, or other rheumatologic disease or any other medical condition or use of medication (e.g., corticosteroids) which might make it difficult for the patient to complete the full course of treatments or to generate an immune response to vaccines. In the case of asthma or chronic obstructive pulmonary disease, taking inhaled corticosteroids that do not require daily systemic corticosteroids is acceptable. Additionally, local acting steroids (topical, inhaled, or intraarticular) will be allowed. Patients on intermittent or short course steroids will be allowed if the dose does not exceed 4 mg of dexamethasone (or equivalent) per day for \\> 7 consecutive days. Systemic steroids must be discontinued at least 7 days prior to the first dose of SLP-01. Premedication for chemotherapy does not apply to this criterion and may be administered as per SOC practice. Any patients receiving steroids should be discussed with the PI to determine if they are eligible for this investigational treatment.\n* History of allogeneic stem cell transplant of solid organ transplant.\n* History of grade ≥3 immune-related adverse events with prior checkpoint inhibitors that, in the investigator's opinion, preclude further IO or vaccine therapy.\n* Untreated or unstable CNS metastases.\n* Known HIV-positive status.\n* History of positive test for Hepatitis B virus surface antigen (HBsAg) and\u002For positive Hepatitis C antibody result with detectable hepatitis C virus (HCV) ribonucleic acid (RNA) indicating acute or chronic infection.\n* Pregnant and\u002For breastfeeding. Women of childbearing potential must have a negative serum\u002Furine pregnancy test within 7 days of study entry.\n\nInclusion Criteria Cohort #4:\n\n* Age ≥ 18 years.\n* ECOG performance status ≤ 1.\n* Histological diagnosis of non-small cell lung carcinoma, stages II, IIIA or IIIB with complete R0 resection. Completed R0 resection within 9 months of surgery.\n* Planned to receive or have received adjuvant immunotherapy for 1 year.\n* Availability of a SignateraTM ctDNA report within 28 days prior to enrollment demonstrating ctDNA-positivity (MRD+). Note: Patients may be pre-screened prior to obtaining ctDNA results to facilitate assay design.\n* Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n* Radiologic confirmation (by conventional imaging) of absence of residual disease and absence of metastasis.\n* Adequate bone marrow and organ function as defined below:\n\n  * WBC ≥ 1.5 K\u002Fcumm\n  * Absolute neutrophil count ≥ 1.0 K\u002Fcumm\n  * Platelets ≥ 50 K\u002Fcumm\n  * Hemoglobin ≥ 8.0 g\u002FdL\n  * Total bilirubin ≤ 1.5 x IULN\n  * AST(SGOT)\u002FALT(SGPT) ≤ 3.0 x IULN\n  * Creatinine clearance \\> 30 mL\u002Fmin by Cockcroft-Gault\n* Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria Cohort #4:\n\n* Receiving any other investigational agents or planning to receive other investigational agents in the neoadjuvant or adjuvant setting.\n* Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty.\n* A psychiatric illness or social situation that would limit compliance with study requirements as determined by the investigator from the medical history, physical exam, and\u002For medical record.\n* Prior or currently active autoimmune disease requiring management with immunosuppression. This includes inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemia, immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, sarcoidosis, or other rheumatologic disease or any other medical condition or use of medication (e.g., corticosteroids) which might make it difficult for the patient to complete the full course of treatments or to generate an immune response to vaccines. In the case of asthma or chronic obstructive pulmonary disease, taking inhaled corticosteroids that do not require daily systemic corticosteroids is acceptable. Additionally, local acting steroids (topical, inhaled, or intraarticular) will be allowed. Patients on intermittent or short course steroids will be allowed if the dose does not exceed 4 mg of dexamethasone (or equivalent) per day for \\> 7 consecutive days. Systemic steroids must be discontinued at least 7 days prior to the first dose of SLP-01. Premedication for chemotherapy does not apply to this criterion and may be administered as per SOC practice. Any patients receiving steroids should be discussed with the PI to determine if they are eligible for this investigational treatment.\n* Known EGFR activating mutations (exon 19 deletion or L858R) or ALK, RET, or ROS1 gene rearrangements in subjects for whom adjuvant targeted therapy is planned.\n* History of allogeneic stem cell transplant or solid organ transplant.\n* History of grade ≥3 immune-related adverse events with prior checkpoint inhibitors that, in the investigator's opinion, preclude further IO or vaccine therapy.\n* Known HIV-positive status.\n* History of positive test for Hepatitis B virus surface antigen (HBsAg) and\u002For positive Hepatitis C antibody result with detectable hepatitis C virus (HCV) ribonucleic acid (RNA) indicating acute or chronic infection.\n* Pregnant and\u002For breastfeeding. Women of childbearing potential must have a negative serum\u002Furine pregnancy test within 7 days of study entry.",{"count":101,"type":21},64,[103],"PHASE1","This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease. The hypothesis of the trial is that synthetic long peptide personalized cancer vaccines will be safe and capable of generating measurable neoantigen-specific T-cell responses enabling ctDNA clearance. The personalized cancer vaccines are composed of synthetic long peptides corresponding to prioritized cancer neoantigens and will be co-administered with poly-ICLC.",[106,27,107,108],"Muscle-Invasive Bladder Carcinoma","Melanoma","Non-small Cell Lung Cancer",[110,111,112,113,27,114,107,115,116],"Personalized cancer vaccine","Solid tumor","Immunotherapy","Bladder cancer","GEC","NSCLC","Non-small cell lung cancer","2026-06-16",{"date":119,"type":42},"2026-06-18",{"date":121,"type":42},"2025-03-20",{"date":123,"type":21},"2034-06-30",{"name":125,"class":49},"Washington University School of Medicine",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":138,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":156},"100598301","phase-2-a-study-of-novel-agents-or-combinations-as-perioperative-treatment-in-participants-with-locally-advanced-resectable-gastroesophageal-adenocarcinoma-100598301","NCT07069712","A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","A Master Protocol of an Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (GEMINI-PeriOp GC)","Inclusion Criteria:\n\n* Histologically documented gastric, GEJ, or esophageal adenocarcinoma with resectable disease\n* Participants who are CLDN18.2-positive and HER2-negative in Sub-study 1 or HER2-positive in Sub-study 2; no specific requirements for Sub-study 3\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate organ and bone marrow function\n* Body weight \\> 35 kg\n\nExclusion Criteria:\n\n* Participants had any prior anti-cancer treatment or surgery for the current gastric, GEJ, or esophageal cancer.\n* Active or prior documented autoimmune or inflammatory disorders requiring systemic treatment with steroids or other immunosuppressive treatment\n* Central nervous system (CNS) pathology\n* Uncontrolled infections\n* Participants with history of (non-infectious) interstitial lung disease (ILD)\u002Fpneumonitis, current ILD\u002Fpneumonitis, or suspected ILD\u002Fpneumonitis\n* History of another primary malignancy\n* Participants with any known or suspicious distant metastasis\n* Uncontrolled hepatitis B and\u002For chronic or active hepatitis B\n* Current or prior use of immunosuppressive medication within 14 days before the first dose of study intervention",{"count":134,"type":21},100,[24],"GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants with locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease.",[27],[139,140,141,142,143,144,145],"Locally Advanced Resectable Gastroesophageal Adenocarcinoma","Gastroesophageal Junction","Neoadjuvant Treatment","Perioperative Treatment","Gastric cancer","Immune checkpoint inhibitors","Chemotherapy","2026-06-12",{"date":148,"type":42},"2026-06-15",{"date":150,"type":42},"2025-07-17",{"date":152,"type":21},"2028-09-06",{"name":154,"class":155},"AstraZeneca","INDUSTRY",70,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":5},"100519429","phase-2-paclitaxel-and-ramucirumab---zanidatamab-in-her2-postive-advanced-gastroesophageal-adenocarcinoma-100519429","NCT06043427","Paclitaxel and Ramucirumab +\u002F- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma","A Randomized Phase II Study of Paclitaxel and Ramucirumab +\u002F- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma","Inclusion Criteria:\n\n* Participants must have histologically or pathologically confirmed gastroesophageal adenocarcinoma (stomach, gastroesophageal junction or esophagus) that is unresectable or metastatic and which must be HER2 positive as confirmed by central testing using FDA-approved HER2 assay. HER2 positive is defined as IHC 3+, or IHC 2+ and FISH positive.\n* Participants must have received and failed at least one prior trastuzumab-containing regimen in combination with platinum-based chemotherapy for treatment of locally advanced or metastatic disease. Failure is defined as demonstrated objective disease progression (radiologic) on the most recently administered HER2 targeting agent.\n* Participants must have presence of measurable or evaluable disease as defined by Response Evaluation Criteria in Solid Tumours (RECIST 1.1).\n* Participants must be considered a suitable candidate for, and able to receive chemotherapy for advanced disease with paclitaxel and ramucirumab.\n* Participants must consent to the provision of samples of blood, serum and plasma in order that the specific correlative marker assays may be conducted.\n* Participants must consent to provision of, and investigator(s) must confirm access to a representative formalin fixed paraffin embedded (FFPE) block of tumour tissue\u002F or a predetermined number of freshly cut slides of representative tumour tissue of adequate amount and quality in order that the central HER2 testing may be done\n* Participants must be ≥ 18 years of age.\n* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Participants must have a life expectancy of at least 12 weeks at the time of study entry\n* Imaging investigations including CT\u002FMRI of chest\u002Fabdomen\u002Fpelvis or other scans as necessary to document all sites of disease must be done within 28 days prior to randomization\n* Participants must have adequate cardiac function by ECHO or MUGA defined as EF ≥ 50%. This is to be performed within 4 weeks (preferred) but no more than 8 weeks prior to randomization\n* Participants must have adequate normal organ and marrow function\n* Participant is able (i.e. sufficiently fluent) and willing to complete the quality of life and\u002For health utility questionnaires in either English or French\n* Participant consent must be appropriately obtained in accordance with applicable local and regulatory requirements.\n* Participant must be accessible for treatment and follow-up. Investigators must assure themselves the participants enrolled on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.\n* In accordance with CCTG policy, protocol treatment is to begin within 2 working days of participant enrollment\n* Participants of childbearing potential must have agreed to use a highly effective contraceptive method for the entire period of study treatment and for at least 7 months after discontinuing study therapy.\n\nExclusion Criteria:\n\n* Participants with a history of other malignancies except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≥ 5 years. Patients with a history of other malignancies detected at an early stage and whom the investigator believes have been curatively treated and are at a low risk of recurrence MAY be eligible\n* Participants receiving therapy in a concurrent clinical study. Patients must agree not to participate in other clinical studies during their participation in this trial while on study treatment\n* Participants with active or uncontrolled intercurrent illness\n* Participants with human immunodeficiency virus infection (positive HIV 1\u002F2 antibodies), active hepatitis B infection (positive HBV surface antigen (HBsAg)) or positive for hepatitis C (HCV) antibody may be considered for enrollment, if infection is adequately controlled in the opinion of the investigator.\n* Any active disease condition which would render the protocol treatment dangerous or impair the ability of the patient to receive protocol therapy\n* Any condition (e.g. psychological, geographical, etc.) that does not permit compliance with the protocol\n* Any unresolved toxicity (CTCAE grade 2 or greater) from previous anti-cancer therapy which in the opinion of the investigator puts the participant at higher than expected risk during protocol treatment. However, participants with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational products in the Investigator's opinion may be included.",{"count":165,"type":21},168,[24],"This study is being done to answer the following question:\n\nCan the chance of gastroesophageal cancer growing or spreading be lowered by adding a drug called zanidatamab to the usual combination of drugs?\n\nWe are doing this study because we want to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as care most people get for gastroesophageal cancer",[27],"2026-06-08",{"date":171,"type":42},"2026-06-09",{"date":173,"type":42},"2024-04-16",{"date":175,"type":21},"2026-12-31",{"name":177,"class":178},"Canadian Cancer Trials Group","NETWORK",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":190,"conditions":191,"keywords":202,"overallStatus":210,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":4},"100639777","phase-1-a-first-in-human-study-of-hh160-in-patients-with-advanced-solid-tumors-100639777","NCT07623369","A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors","An Open-Label, Multicenter, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Preliminary Antitumor Activity of HH160 in Patients With Advanced Solid Tumors","Key Inclusion Criteria\n\n1. Adults aged 18 to 75 years with signed informed consent.\n2. Histologically or cytologically confirmed advanced solid tumors meeting phase-specific disease requirements.\n3. At least 1 measurable lesion per RECIST v1.1.\n4. Eastern Cooperative Oncology Group Performance Status (ECOG) Performance Status of 0 or 1 with life expectancy ≥ 12 weeks.\n5. Adequate organ function based on protocol-specified laboratory criteria.\n\nKey Exclusion Criteria\n\n1. Active leptomeningeal disease or uncontrolled\u002Funtreated brain metastases.\n2. History of severe hypersensitivity reactions to monoclonal antibodies, bispecific antibodies, trispecific antibodies, or study drug components.\n3. Other malignancy within 3 years prior to first dose, except specified curatively treated cancers.\n4. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring frequent drainage.\n5. Significant bleeding risk, severe coagulopathy, gastrointestinal hemorrhage, or recent pulmonary hemorrhage\u002Fhemoptysis.\n\nNOTE: Other eligibility criteria may apply.","75 Years",{"count":188,"type":21},56,[103],"This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors. The study will also identify the recommended dose for future studies. The trial includes two phases and is expected to last about 4 years, with treatment and follow-up lasting approximately 6-12 months each.",[192,108,193,194,195,196,197,198,199,200,201,27],"Solid Tumor","Hepatocellular Carcinoma","Colorectal Cancer","Head and Neck Squamous Cell Carcinoma","Renal Cell Carcinoma","Endometrial Cancer","Cervical Cancer","Small-cell Lung Cancer","Triple Negative Breast Cancer","Urothelial Carcinoma",[203,204,108,115,193,205,194,206,33,195,196,207,197,198,199,200,208,201,27,209],"HH160","PD-1×CTLA-4×VEGF-A Antibody","HCC","CRC","RCC","TNBC","Ovarian Cancer","NOT_YET_RECRUITING","2026-05-29",{"date":213,"type":42},"2026-06-03",{"date":215,"type":21},"2026-06",{"date":217,"type":21},"2028-08",{"name":219,"class":155},"Huahui Health",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":22,"phases":230,"briefSummary":231,"conditions":232,"keywords":233,"overallStatus":210,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":92},"100638269","phase-2-restage-repurposing-statins-to-improve-outcomes-in-gastroesophageal-cancer-trial-100638269","NCT07625930","RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial","RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial: A Phase II Randomized Open-Label Trial of Perioperative Simvastatin Plus Standard-of-Care Systemic Therapy in Gastroesophageal Adenocarcinoma","RESTAGE","Inclusion Criteria:\n\n1. Signed, informed consent.\n2. Age, 18 years or older.\n3. Histological diagnosis of adenocarcinoma or poorly differentiated carcinoma of the esophagus or EGJ.\n4. The tumour must be deemed potentially resectable by the surgical team. This assessment is based on complete staging imaging studies (detailed below) - clinical staging of the tumor and ruling out metastatic disease.\n5. Locally advanced disease as defined per AJCC\u002FUICC 8th edition37: stage IIA, IIB, III, IVA (T1-4a N2-3).\n6. Eligibility for standard-of-care perioperative systemic therapy with FLOT+\u002F-D.\n7. Life expectancy greater than 3 months.\n8. ECOG performance status \\\u003C 2.\n\nExclusion Criteria:\n\n1. Prior esophageal or gastric malignancy.\n2. History of allergic reactions to simvastatin or atorvastatin or similar chemical or biological compounds.\n3. Ongoing cholesterol-lowering therapy (statins, fibrates, ezetimibe, PCSK9 inhibitors), in which case the patient is offered enrollment in the observational arm.\n4. Hepatic dysfunction (alanine aminotransferase level more than three times the upper limit of the normal range) or renal dysfunction (creatinine level more than three times the upper limit of the normal range).\n5. Predisposing factors for rhabdomyolysis: hypothyroidism, reduced renal function, muscle disease, or excessive alcohol consumption AND creatine kinase up to less than five times the upper limit (measured in the presence of predisposing factors).\n6. Concurrent medication with potent CYP3A4-inhibitors, e.g. ketokonazole, erythromycin, gemfibrozil, cyclosporine, or danazol.\n7. Pre-existing medical conditions precluding treatment, including any contraindication systemic chemotherapy or major surgery.\n8. Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule, discussed before registration in the trial.\n9. Pregnant and breastfeeding women.\n10. Unwillingness to undergo per-protocol investigations or treatments.",{"count":229,"type":21},184,[24],"Esophageal and gastroesophageal junction cancers are serious diseases with limited cure rates, even when patients receive chemotherapy and surgery. New ways to improve treatment are urgently needed.\n\nThis study will test whether adding a commonly used cholesterol-lowering medication, simvastatin, to standard cancer treatment can improve outcomes. Simvastatin is widely used, safe, and inexpensive. Research suggests that it may also slow cancer growth by blocking pathways that cancer cells rely on for survival.\n\nIn this trial, patients will receive standard chemotherapy (with or without immunotherapy) before surgery. Half of the patients will also take simvastatin daily for up to two years. Researchers will compare how well tumors respond to treatment and whether patients remain cancer-free longer.\n\nIf successful, this approach could offer a simple and accessible way to improve survival for patients with these cancers without adding significant side effects or cost.",[27],[234,235,236,27],"Esophageal cancer","Gastroesophageal junction cancer","Statin",{"date":238,"type":42},"2026-06-04",{"date":240,"type":21},"2027-01",{"date":242,"type":21},"2031-04",{"name":244,"class":49},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":22,"phases":254,"briefSummary":255,"conditions":256,"keywords":257,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":272},"100634815","phase-1-a-phase-1-study-evaluating-disp-10-in-participants-with-advanced-gastrointestinal-cancers-100634815","NCT07544589","A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers","A Phase 1 Study to Evaluate the Safety and Efficacy of DISP-10 in Participants With Advanced Gastrointestinal Cancers","Key Inclusion Criteria:\n\n1. Histologically confirmed advanced or metastatic esophageal, gastroesophageal junction, gastric adenocarcinoma, or colorectal adenocarcinoma\n2. Measurable disease according to RECIST v1.1 and at least 1 additional site of disease amenable to biopsy\n3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n4. Aged ≥18 years at time of signing informed consent\n5. Adequate organ function\n\nKey Exclusion Criteria:\n\n1. Previous solid organ or hematopoietic cell transplant\n2. Evidence of rapid disease progression, defined as radiographic or clinical progression within 3 months of the most recent prior line of therapy\n3. Known history of hepatitis B or HIV infection\n4. Previous or concurrent malignancy except if curatively treated more than 3 years prior to enrollment\n5. Known active central nervous system (CNS) metastases\n6. Clinically significant pleural or pericardial effusion or peritoneal carcinomatosis\n7. Active treatment with antiviral agents\n8. History of severe hypersensitivity to fludarabine or cyclophosphamide\n9. Prior therapies\u002Ftreatments with oncolytic viruses or T cell derived cellular therapy",{"count":253,"type":21},66,[103],"This is a Phase 1, multicenter, open-label study of DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (ide-cel, BCMA-directed chimeric antigen receptor \\[CAR\\] T), in adult participants with advanced gastrointestinal (GI) cancers.\n\nThe study will consist of 2 parts: dose-escalation (Part 1) and dose-expansion (Part 2). Part 1 of the study will evaluate the safety and tolerability of increasing dose levels of DISP-10 to establish the recommended dose for expansion (RDE); Part 2 will evaluate the safety and efficacy of DISP-10 in participants treated at the RDE.",[194,67,66,27],[258,259,260,261,262,263],"CAR T","Adenovirus","ABECMA","BCMA","gastrointestinal cancer","CAR-T","2026-05-27",{"date":211,"type":42},{"date":267,"type":21},"2026-04",{"date":269,"type":21},"2046-04",{"name":271,"class":155},"Dispatch Biotherapeutics",3,{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":22,"phases":282,"briefSummary":283,"conditions":284,"keywords":287,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":300},"100552196","phase-1-substudy-06c-a-study-of-investigational-agents-with-pembrolizumab-mk-3475-and-chemotherapy-in-participants-with-first-line-locally-advanced-unresectablemetastatic-gastroesophageal-adenocarcinoma-mk-3475-06ckeymaker-u06-100552196","NCT06469944","Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable\u002FMetastatic Gastroesophageal Adenocarcinoma (MK-3475-06C\u002FKEYMAKER-U06)","A Phase 1\u002F2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With 1L Locally Advanced Unresectable\u002FMetastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma): Substudy 06C","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has histologically and\u002For cytologically confirmed diagnosis of previously untreated locally advanced unresectable or metastatic first-line (1L) gastroesophageal adenocarcinoma\n* Is not expected to require tumor resection during the treatment course\n* Tumor tissue must be confirmed as negative for human epidermal growth factor receptor 2 (HER2) expression as classified by American Society of Clinical Oncology\u002FCollege of American Pathologists (ASCO-CAP) guidelines\n* Core\u002Fexcisional biopsy of a tumor lesion not previously irradiated has been provided\n* Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline\n* Participants with endocrine-related AEs who are adequately treated with hormone replacement therapy are eligible\n* Has adequate organ function\n* Has measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as determined by the local site investigator\u002Fradiology assessment and verified by blinded independent central review (BICR)\n* Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 3 days prior to the first dose of study intervention\n* Has a life expectancy of at least 6 months\n* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to allocation\u002Frandomization\n* Participants with history of Hepatitis C Virus (HCV) infection are eligible if HCV viral load is undetectable at screening\n* Human Immunodeficiency Virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has squamous cell or undifferentiated gastroesophageal cancer.\n* Has had previous therapy for locally advanced unresectable or metastatic gastric\u002Fgastroesophageal junction (GEJ)\u002Fesophageal adenocarcinoma\n* Has experienced weight loss \\>20% over 3 months before the first dose of study intervention\n* Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and\u002For blepharitis, or severe corneal disease that prevents\u002Fdelays corneal healing\n* Has Grade ≥2 peripheral neuropathy\n* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease\n* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease within 6 months preceding study intervention\n* Has accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to enrollment\n* Has history of human immunodeficiency virus (HIV) infection with Kaposi's sarcoma and\u002For Multicentric Castleman's Disease\n* Has received prior treatment with a trophoblast antigen 2 (TROP2)-targeted or anti-human epidermal growth factor receptor 3 (HER3) targeted agents\n* Has received prior treatment with a topoisomerase I inhibitor-based antibody-drug conjugate (ADC) and\u002For a topoisomerase I inhibitor-based chemotherapy\n* Has received prior systemic anticancer therapy within 4 weeks before the first dose of study intervention\n* Has received prior therapy with an anti-Programmed Cell Death Protein 1 (PD-1), anti-Programmed Cell Death-Ligand 1 (PD-L1), anti-Programmed Cell Death-Ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (TCR)\n* Has received prior radiotherapy within 2 weeks of start of study intervention, or has radiation related toxicities, requiring corticosteroids\n* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention\n* Has received a strong inducer\u002Finhibitor of CYP3A4 that cannot be discontinued\n* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration\n* Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention\n* Has known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis\n* Has Severe hypersensitivity (≥Grade 3) to pembrolizumab, sacituzumab tirumotecan, patritumab deruxtecan, or other biologic therapy, chemotherapy (ie, oxaliplatin, fluorouracil, capecitabine), leucovorin, levoleucovorin, or any of their excipients\n* Has active autoimmune disease that has required systemic treatment in the past 2 years\n* Has history of (noninfectious) pneumonitis or interstitial lung disease (ILD) that required steroids or has current pneumonitis or ILD, or where suspected ILD or pneumonitis cannot be ruled out by imaging at screening\n* Has an active infection requiring systemic therapy\n* Has concurrent active hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] positive and\u002For detectable HBV DNA) and hepatitis C virus (defined as anti-hepatitis C virus \\[HCV\\] Ab positive and detectable HCV ribonucleic acid \\[RNA\\] infection or a known history of hepatitis B and\u002For C infection\n* Has history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's ability to cooperate with the requirements of the study\n* Has gastrointestinal (GI) obstruction, poor oral intake, or difficulty in taking oral medication\n* Has poorly controlled diarrhea\n* Has had a major surgery or significant traumatic injury within 4 weeks before the first dose of study intervention\n* Has history of allogeneic tissue\u002Fsolid organ transplant\n* Has not adequately recovered from major surgery or has ongoing surgical complications",{"count":281,"type":21},160,[103,24],"This is a phase 1\u002F2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma.\n\nThis substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for investigational agents in combination with chemotherapy and immunotherapy. There is no formal hypothesis in this study.",[140,27,285,286],"Esophageal Neoplasms","Esophageal Cancer",[288,289,290],"Programmed Cell Death-1 (PD1, PD-1)","Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)","Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)","2026-05-21",{"date":293,"type":42},"2026-05-26",{"date":295,"type":42},"2024-09-20",{"date":297,"type":21},"2029-09-12",{"name":299,"class":155},"Merck Sharp & Dohme LLC",51,{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":22,"phases":310,"briefSummary":311,"conditions":312,"keywords":313,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":323},"100550353","phase-1-substudy-06d-combination-therapies-in-second-line-2l-gastroesophageal-adenocarcinoma-mk-3475-06dkeymaker-u06-100550353","NCT06445972","Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D\u002FKeymaker-U06)","A Phase 1\u002F2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants With Advanced\u002FMetastatic Gastroesophageal Adenocarcinoma: Substudy 06D","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has histologically and\u002For cytologically confirmed diagnosis of previously treated, second line (2L) (received first line (1L) treatment) gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma\n* Has metastatic disease or locally advanced, unresectable disease\n* Has experienced documented objective radiographic or clinical disease progression during or after 1L therapy containing any platinum\u002Ffluoropyrimidine doublet with or without immunotherapy\n* Tumor tissue must be confirmed as negative for HER2 expression (IHC 0\u002F1+ or IHC2+\u002Fin situ hybridization negative) as classified by American Society of Clinical Oncology\u002FCollege of American Pathologists (ASCO-CAP) guidelines\n* Can provide a core\u002Fexcisional biopsy of a tumor lesion not previously irradiated (collected from a biopsy performed after the most recent systemic anticancer therapy regimen)\n* AEs due to previous anticancer therapies must be ≤Grade 1 or baseline (except alopecia and vitiligo). Endocrine-related AEs adequately treated with hormone replacement are acceptable\n* Has Eastern Cooperative Oncology Group performance status of 0 or 1\n* Has a life expectancy of at least 3 months\n* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to allocation\u002Frandomization\n* Participants with history of Hepatitis C Virus (HCV) infection are eligible if HCV viral load is undetectable at screening\n* Human Immunodeficiency Virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has squamous cell or undifferentiated gastroesophageal cancer\n* Has experienced weight loss \\>20% over 3 months before the first dose of study intervention\n* Has history of documented severe dry eye syndrome, severe Meibomian gland disease and\u002For blepharitis, or severe corneal disease that prevents\u002Fdelays corneal healing\n* Has Grade ≥2 peripheral neuropathy\n* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease\n* Has a serious or nonhealing wound or peptic ulcer or bone fracture within 28 days prior to allocation\u002Frandomization\n* Has a bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection (hemicolectomy or extensive small intestine resection with chronic diarrhea)\n* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease\n* Has experienced any arterial thrombotic event, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack, within 6 months prior to allocation\u002Frandomization\n* Has uncontrolled arterial hypertension ≥150\u002F≥90 mm mercury (Hg)\n* Has accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to enrollment\n* Has undergone major surgery within 28 days prior to allocation\u002Frandomization, or central venous access device placement within 7 days prior to allocation\u002Frandomization or planned major surgery following initiation of study treatment\n* Is receiving therapeutic anticoagulation with warfarin, low-molecular weight heparin or similar agents\n* Is receiving chronic therapy with nonsteroidal anti-inflammatory agents or other antiplatelet agents\n* Has a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism during the 3 months prior to allocation\u002Frandomization\n* Has significant bleeding disorders, vasculitis, or had a significant bleeding episode from the gastrointestinal (GI) tract within 3 months prior to study entry\n* Has history of GI perforation and\u002For fistulae within 6 months prior to allocation\u002Frandomization\n* HIV-infected participants with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease\n* Has received prior treatment with a trophoblast cell-surface antigen 2 (TROP2)- or HER3-targeted agent, topoisomerase 1 inhibitor-based ADC and\u002For a topoisomerase 1 inhibitor-based chemotherapy, or any previous systemic therapy targeting vascular endothelial growth factor (VEGF) or the vascular endothelial growth factor receptor (VEGFR) signaling pathways\n* Has received prior systemic anticancer therapy within 4 weeks before the first dose of study intervention\n* Has received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids\n* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed\n* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration\n* Has known additional malignancy that is progressing or has required active treatment within the past 3 years. Basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded\n* Has known active central nervous system metastases and\u002For carcinomatous meningitis\n* Has an active infection requiring systemic therapy\n* Has concurrent active Hepatitis B (defined as HBsAg positive and\u002For detectable HBV deoxyribonucleic acid) and Hepatitis C virus (defined as anti-HCV antibody positive and detectable HCV ribonucleic acid) infection\n* History of (noninfectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease, or where suspected ILD or pneumonitis cannot be ruled out by imaging at screening\n* Has severe hypersensitivity (Grade ≥3) to MK-2870, or HER3-DXd, any of their excipients, and\u002For to another biologic therapy\n* Has not adequately recovered from major surgery or have ongoing surgical complications",{"count":309,"type":21},210,[103,24],"This is a phase 1\u002F2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, and HER3-DXD plus ramucirumab versus ramucirumab plus paclitaxel for the treatment of participants with advanced or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, or esophageal adenocarcinoma who have failed 1 prior line of therapy. This is an estimation study, and no formal hypothesis testing will be performed.",[140,27,285,286],[314,289,290],"Programmed Cell Death 1 (PD1, PD-1)","2026-05-08",{"date":317,"type":42},"2026-05-12",{"date":319,"type":42},"2024-08-07",{"date":321,"type":21},"2030-08-08",{"name":299,"class":155},45,{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":22,"phases":333,"briefSummary":334,"conditions":335,"keywords":348,"overallStatus":210,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":354,"completionDateStruct":355,"leadSponsor":357,"locationsCount":4},"100633678","phase-1-phase-12-study-of-bhb810-in-advanced-gastric-and-gej-adenocarcinoma-100633678","NCT07529808","Phase 1\u002F2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma","Phase 1\u002F2, Open-Label, Multicenter, Dose Escalation and Expansion Study of BHB810 in Participants With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n* Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the ICF.\n* Histologically confirmed advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on, was nonresponsive to, or for which no standard or available curative therapy exists.\n\n  * Participants in Phase 1 Backfill Cohorts \\& Phase 2 must be CDH17-positive by central testing.\n  * Other gastrointestinal (GI) tumor types may be enrolled in Backfill Cohorts and Phase 2.\n* At least 1 measurable target lesion at baseline per RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)\n* Provision of FFPE archival tumor tissue. Additional fresh biopsies at screening are required in Phase 1 Backfill Cohorts and Phase 2.\n* Adequate organ and marrow function as defined in the protocol\n\nExclusion Criteria:\n\n* Prior cancer treatment as follows, relative to the first planned dose of trial intervention:\n\n  * Chemotherapy or targeted therapy withing 4 weeks or 5-halflives (whichever is shorter)\n  * Monoclonal antibody-based therapy (including ADCs) within 4 weeks\n  * Immune checkpoint inhibitors within 4 weeks\n  * Wide-field radiation therapy (\\>30% marrow-bearing bones) within 4 weeks or \\\u003C 2 weeks of focal palliative radiation to nontarget lesions\n* Prior treatment with a CDH17-directed therapy or an ADC with an auristatin (MMAE or MMAF)\n* Known hypersensitivity or allergic reaction to BHB810 or it's excipients\n* Left ventricular ejection fraction \\\u003C50% or history of congestive heart failure Class III\u002FIV\n* QTc interval \\> 470 msec, history of risk factors for Torsade de Pointes, or taking a medication known to prolong QT\u002FQTc\n* Pregnant or breastfeeding females, or if you or your partner are planning to become pregnant\n* Known or suspected brain metastases, leptomeningeal disease, or spinal cord compression. Participants with stable, treated brain metastases may be enrolled.\n* Current treatment with a strong CYP3A4 inhibitor or inducer, Pgp inhibitor, or CYP3A4 sensitive substrate within 2 weeks of first dose of trial intervention\n* Any condition that may compromise participant safety, compliance, or interfere with the evaluation of the study drug.",{"count":332,"type":21},164,[103,24],"This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how well the study drug works, how the study drug moves into, through, and out of the body, and how your body reacts to the study drug. Participants will get an IV infusion of BHB810 every 2 weeks while on study treatment.",[336,67,337,27,338,339,340,341,342,343,344,345,346,347],"Gastric Cancer","Gastric (Stomach) Cancer","Gastroesophageal Cancer (GC)","Gastroesophageal Junction (GEJ) Adenocarcinoma","Gastroesophageal Junction (GEJ) Cancer","Gastrointestinal Cancer Metastatic","Gastrointestinal Adenocarcinoma","Gastrointestinal Cancers","Colorectal (Colon or Rectal) Cancer","Pancreatic Cancer","CDH17-positive Advanced Solid Tumors","Advanced Gastric Cancer",[349,350,351],"Antibody Drug Conjugate (ADC)","Monomethyl Auristatin E (MMAE)","CDH17 protein","2026-05-05",{"date":315,"type":42},{"date":215,"type":21},{"date":356,"type":21},"2028-12",{"name":358,"class":155},"BigHat Biosciences, Inc.",{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":365,"eligibilityCriteria":366,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":367,"targetDuration":4,"studyType":22,"phases":369,"briefSummary":370,"conditions":371,"keywords":4,"overallStatus":210,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":4},"100615313","phase-2-aacr-adaptive-biomarker-driven-organ-preservation-trial-in-gastroesophageal-adenocarcinomas-100615313","NCT07290985","AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas","AACR Adaptive Biomarker-Driven Organ Preservation Trial In Gastroesophageal Adenocarcinomas (AACR-ADOPT-GEA)","AACR-ADOPT-GEA","Inclusion Criteria:\n\n* Histologically confirmed, resectable adenocarcinoma of the stomach, esophagus, or gastroesophageal junction (Stage II or higher, T2N0 with high-risk features).\n* Complete surgical resection deemed achievable by multidisciplinary evaluation.\n* Willingness to undergo tumor biopsies for biomarker analysis (HER2, FGFR2b, PD-L1, MSI) at screening, progression, or pre\u002Fpost- surgery.\n* Life expectancy ≥ 24 weeks. Eastern Cooperative Oncology Group (ECOG) performance status ≤1.\n* Adequate organ function:\n\n  * Hematologic: absolute neutrophil count (ANC) ≥1.5 ×10⁹\u002FL, platelets ≥100 ×10⁹\u002FL, hemoglobin ≥ 8 g\u002FdL\n  * Hepatic: aspartate aminotransferase (AST)\u002F alanine aminotransferase (ALT) ≤2.5 × ULN, total bilirubin ≤1.5 × upper limit of normal (ULN) (≤2.5 × ULN for Gilbert's)\n  * Renal: creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL\u002Fmin\u002F1.73 m²\n* Willingness for blood samples to be drawn for research purposes.\n* Baseline dihydropyrimidine dehydrogenase (DPD) testing per local guidelines; dosing of 5-FU adjusted for deficiency.\n* Use of two effective contraception methods for women of childbearing potential and men during and 4 months after study; pregnant or breastfeeding women excluded.\n* Must have the ability to understand and the willingness to sign a written informed consent document.\n* Willingness and able to comply with the protocol for the duration of the study, including attending scheduled visits, examinations, the screening procedure, and having their tumor and blood molecularly characterized.\n* Understands they must meet all Inclusion and Exclusion criteria in the sub-protocol for the treatment for which they will be later assigned\n\nAdditional inclusion criteria for all sub-studies:\n\n• FFPE tumor sample tested at a central laboratory confirming PD-L1 Tumor Area Positivity (TAP) score ≥1%.\n\nAdditional inclusion criteria specific to HER2 sub-study:\n\n* Histologically confirmed diagnosis of resectable (i.e., radical surgery eligible), HER2-positive (defined as 3+ HER2 expression by IHC or 2+ HER2 expression by immunohistochemistry (IHC) with in situ hybridization (ISH)-positivity per central assessment) adenocarcinoma of the stomach or esophagus, including the gastroesophageal junction.\n* Formalin-fixed, paraffin-embedded (FFPE) tumor sample tested at a central laboratory confirming HER2-positive status.\n* Left ventricular ejection fraction (LVEF) ≥50% as determined by either echocardiogram or multiple gated acquisition scan (MUGA).\n\nExclusion criteria:\n\n* Unresectable disease, peritoneal dissemination, and\u002For positive cytology on laparoscopy.\n* Peripheral neuropathy ≥ Grade 2.\n* Active infection.\n* Chronic growth factor support for white blood cells or granulocytes.\n* Concurrent anti-cancer therapy (exceptions: supportive care medications ≥1 month prior, low molecular weight heparin, prior adjuvant hormonal therapy \\>3 years, palliative radiation\n\n  ≤14 days prior).\n* Local\u002Fsystemic therapy for current gastroesophageal diagnosis (except one FLOX\u002F mFOLFOX6 dose during screening).\n* Significant medical conditions compromising safety or protocol compliance.\n* Preexisting cardiac conditions.\n* Stroke, transient ischemic attack (TIA), or myocardial infarction within 6 months.\n* Prior FGFR-targeted therapy.\n* Prior HER2-targeted therapy (except \\>5 years prior for breast cancer).\n* Prior checkpoint inhibitor therapy (anti-PD-1\u002FPD- L1\u002FPD-L2).\n* Conditions preventing safe surgery\u002Fbiopsy.\n* Malabsorption syndrome or inability to swallow oral medication.\n* Pregnant or nursing women\n* History of stem cell or organ transplant.\n* Major surgery within 14 days.\n* Other malignancy within 3 years (exceptions: basal\u002Fsquamous cell carcinoma, in situ malignancy, low-risk prostate cancer).\n* Systemic corticosteroids \\>10 mg prednisone\u002F day or immunosuppressive therapy ≤14 days prior (exceptions: adrenal replacement, topical\u002F inhaled, short prophylactic courses).\n* HIV with CD4 \\\u003C350, active hepatitis B or C.\n* Active or relapsing autoimmune disease (exceptions: controlled type I diabetes, hypothyroidism on replacement, controlled celiac disease, mild skin disease, other non- recurrent diseases).\n\nAdditional exclusion criteria for all sub-studies:\n\n* History of hypersensitivity or contraindications to any active substance\u002Factive ingredient of any study medication, including chemotherapy components monoclonal antibodies, recombinant proteins, and\u002For any of the excipients listed in the ingredients of any drug formulation\n* Poorly controlled seizures\n* Clinically significant bleeding (CTCAE ≥ Grade 3) from the gastrointestinal (GI) tract within 4 weeks prior to enrollment.\n* Administered a live vaccine ≤ 4 weeks prior to enrollment\n* History of interstitial lung disease or non-infectious pneumonitis, or with severe dyspnea at rest or requiring supplementary oxygen therapy.\n* Treated with another investigational product within 28 days of enrolment.\n\nExclusion criteria specific to HER2 sub-study:\n\n* Total lifetime anthracycline load exceeding 360 mg\u002Fm² of doxorubicin or equivalent\n* QTc Fridericia (QTcF) \\>470 ms. Note: For subjects with longer QTcF on initial electrocardiogram (ECG), follow-up ECG may be performed in triplicate to determine eligibility (e.g., after correction of electrolyte abnormalities, or discontinuation of QT-prolonging drugs).\n* Ongoing Grade 2 or greater diarrhea",{"count":368,"type":21},121,[24],"This study will test a new personalized treatment approach for patients with stomach or esophageal cancer. It will take place in two stages and aims to find the best combination of chemotherapy, immunotherapy, and targeted drugs based on each patient's tumor biomarkers.\n\nUpon enrollment onto the study, patients will consent to tumor biomarker testing and may receive one cycle of standard chemotherapy while awaiting results. Those with a matching biomarker will join the corresponding treatment group that combines chemotherapy, an immune checkpoint inhibitor, and\u002For a targeted therapy. In Stage I of the study, treatment lasts about four months before surgery, followed by an additional eight months of therapy for a total of one year.\n\nThe most effective treatments from Stage I will be studied further in Stage II of the study to see whether some patients can safely avoid surgery. Those patients enrolled during Stage II will receive four months of the same combination treatment (chemotherapy, an immune checkpoint inhibitor, and\u002For a targeted therapy) but may be eligible to skip surgery if their cancer completely disappears after pre-surgery therapy. All patients will then receive an additional eight months of therapy and those who skipped surgery will be closely monitored with scans and endoscopies.",[27],"2026-04-02",{"date":374,"type":42},"2026-04-07",{"date":376,"type":21},"2026-05-01",{"date":378,"type":21},"2028-12-01",{"name":380,"class":49},"American Association for Cancer Research",{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":22,"phases":389,"briefSummary":390,"conditions":391,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":92},"100495629","phase-1-response-adapted-neoadjuvant-therapy-in-gastroesophageal-cancers-rant-gc-trial-100495629","NCT05733689","Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)","Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) - a Phase Ib Feasibility Trial","Inclusion Criteria:\n\n* Patients must have histologically or cytologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (GEA). Other GE histologies which are treated per NCCN guidelines for neoadjuvant treatment are eligible.\n* Must have Stage IB, II or Stage III GEA eligible for (neo)adjuvant doublet or triplet chemotherapy for up to 6 months.\n* Age ≥ 18 years Because the safety or efficacy of neoadjuvant chemotherapy for LGEA has not been tested or established for patients \\\u003C18 years of age, children are excluded from this study but will be eligible for future pediatric trials, if applicable.\n* Performance status: ECOG performance status ≤2\n* Life expectancy of greater than 6 months\n* Adequate organ and marrow function as defined below:\n\n  1. hemoglobin ≥ 7g\u002FdL\n  2. absolute neutrophil count ≥ 1,500\u002FmcL\n  3. platelets ≥ 80,000\u002Fmcl\n  4. total bilirubin within normal institutional limits\n  5. AST(SGOT)\u002FALT(SPGT) ≤ 5 X institutional upper limit of normal\n  6. creatinine \\\u003C2 X ULN\n* Docetaxel can cause fetal harm and irinotecan is known to be teratogenic. Since these compounds are part of the treatment regimens, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n\n  1\\. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n  1. Has not undergone a hysterectomy or bilateral oophorectomy; or\n  2. Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).\n* Ability to understand and the willingness to sign a written informed consent. 1. Both men and women and members of all races and ethnic groups are eligible for this trial. Non-English speaking, deaf, hard of hearing and illiterate individuals are eligible for this trial.\n\nExclusion Criteria:\n\n* Patients may not be receiving any other investigational agents.\n* Patients with known distant metastases from GEA.\n* History of allergic reactions attributed to agents used in study.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* History of another primary cancer which requires active treatment or is expected to require treatment within 12 months after enrollment.\n* Inability to comply with study and follow-up procedures as judged by the Investigator.\n* Patients who are pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.\n* Patients with prior organ\u002Fbone marrow\u002Fnon-autologous stem cell transplants",{"count":50,"type":21},[103],"This is a phase 1b prospective, single arm, open-label trial determining the efficacy and feasibility of using a response-guided approach to help guide neoadjuvant chemotherapy in subjects with Stage IB, II or Stage III adenocarcinoma of the stomach or gastroesophageal junction (GEA).",[27],"2026-03-06",{"date":394,"type":42},"2026-03-10",{"date":396,"type":42},"2025-06-27",{"date":398,"type":21},"2027-06",{"name":400,"class":49},"University of California, Irvine",{"id":402,"slug":403,"hasResults":11,"nctId":404,"briefTitle":405,"officialTitle":405,"acronym":406,"eligibilityCriteria":407,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":22,"phases":410,"briefSummary":411,"conditions":412,"keywords":4,"overallStatus":210,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":4},"100613395","phase-2-adebrelimab-combined-with-induction-chemotherapy-or-shr-8068-for-mismatch-repair-deficientmicrosatellite-instability-high-dmmrmsi-h-locally-advanced-gastricgastroesophageal-junction-adenocarcinomaa-randomized-non-comparative-phase-2-study-100613395","NCT07266025","Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient\u002FMicrosatellite Instability-High (dMMR\u002FMSI-H) Locally Advanced Gastric\u002FGastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study","CATALIS","Inclusion Criteria:\n\n* Male or female, age ≥ 18 years\n* Pathologically confirmed gastric or gastro-oesophageal-junction adenocarcinoma (Siewert II and III only)\n* dMMR confirmed by IHC or MSI-H confirmed by PCR\n* Investigator-assessed potentially curative resection feasible before study entry\n* CT or MRI clinical stage cT ≥ 2 N any M0 per AJCC 8th edition; laparoscopy with peritoneal washing cytology (and peritoneal biopsy if indicated) recommended to exclude peritoneal metastasis\n* ECOG performance status 0-2\n* Able to swallow tablets\n* Expected survival ≥ 6 months\n* Laboratory values within 7 days before randomisation:\n\nANC \\> 1.5 × 10⁹\u002FL, Hb ≥ 80 g\u002FL, PLT ≥ 75 × 10⁹\u002FL Serum creatinine ≤ 1.5 × ULN or eGFR ≥ 60 mL\u002Fmin\u002F1.73 m² ALT and AST ≤ 2.5 × ULN; total bilirubin ≤ 1.5 × ULN (or TBIL \\> 1.5 × ULN with direct bilirubin ≤ ULN); albumin ≥ 25 g\u002FL INR or PT ≤ 1.5 × ULN and aPTT ≤ 1.5 × ULN (or on anticoagulation within therapeutic range)\n\n* Signed written informed consent; able to comply with protocol visits, treatment, labs, biospecimen collection\n* WOCBP must have negative serum pregnancy test within 72 h before randomisation, not breastfeeding, and use highly effective contraception from screening until 2 months after last adebrelimab\u002FSHR-8068 or 6 months after last chemotherapy, whichever is longer\n* Men with pregnant partners or WOCBP partners must be surgically sterile or use highly effective contraception during study and for same post-treatment periods; no sperm donation allowed\n\nExclusion Criteria:\n\n* Tumour histology squamous-cell, neuro-endocrine, or other non-adenocarcinoma types\n* Unresectable disease (tumour-related or surgical contraindication) or subject refuses surgery\n* Tumour requiring transthoracic surgical approach\n* CNS metastases and\u002For carcinomatous meningitis\n* Prior anti-gastric-cancer therapy (surgery, radiotherapy, chemotherapy, targeted, immunotherapy) except bypass for obstruction\n* Previous malignancy or concurrent malignancy except completely excised basal\u002Fsquamous skin cancer, superficial bladder cancer, or in-situ prostate\u002Fcervix\u002Fbreast cancer disease-free ≥ 5 years\n* Cardiac conditions:\n\nNYHA class \\> II or LVEF \\\u003C 50 % on echo Unstable angina MI within 1 year Resting QTc \\> 450 ms (M) or \\> 470 ms (F) Clinically significant ECG abnormalities, complete LBBB, 3rd-degree AV block, 2nd-degree AV block, PR \\> 250 ms Risk factors for QT prolongation (HF, hypokalaemia, congenital long-QT syndrome, family history of long QT or sudden death \\\u003C 40 y, concomitant QT-prolonging drugs)\n\n* History of GI perforation, intra-abdominal abscess, or bowel obstruction within 3 months or imaging\u002Fclinical signs of obstruction\n* Clinically significant bleeding or bleeding diathesis within 3 months (e.g. GI bleeding, haemorrhagic gastritis, vasculitis); positive faecal occult blood must be endoscopically cleared if still positive on repeat testing (unless gastroscopy within 3 months shows no lesion)\n* Arterial or venous thrombo-embolic event within 6 months (stroke, TIA, intracranial haemorrhage, cerebral infarction)\n* Hypersensitivity to any study-drug component\n* Severe hypersensitivity history to any monoclonal antibody\n* Pregnant or lactating women\n* Positive HIV antibody\n* Active hepatitis (HBsAg positive with HBV DNA ≥ 500 IU\u002FmL; HCV antibody positive with HCV RNA \\> ULN)\n* Prior therapy targeting CTLA-4\u002FPD-1\u002FPD-L1 or other T-cell co-stimulatory\u002Fimmune-checkpoint pathways (including therapeutic vaccines)\n* Active autoimmune disease or autoimmune disease with relapse risk within 2 years (except stable hypothyroidism on replacement or well-controlled type 1 diabetes on insulin)\n* History of idiopathic pulmonary fibrosis, drug-related pneumonia, organising pneumonia (BOOP\u002FCOP), or CT evidence of active pneumonia at screening\n* Live attenuated vaccine within 4 weeks before first study dose or expected need during study\n* Immunodeficiency disorder or chronic systemic corticosteroids or other immunosuppressive therapy within 7 days before first dose (includes prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, anti-TNF agents)\n* Any condition that, in the investigator's opinion, increases study risk, interferes with protocol conduct, or compromises informed consent or compliance",{"count":409,"type":21},30,[24],"This is a randomized, non-comparative, open-label, two-arm phase II clinical trial designed to evaluate the efficacy and safety of neoadjuvant therapy with adebrelimab plus induction chemotherapy versus adebrelimab plus SHR-8086 in patients with dMMR\u002FMSI-H gastric or gastroesophageal junction adenocarcinoma.",[67,27,413,112],"Mismatch Repair Deficient or MSI-High Solid Tumors","2026-01-24",{"date":416,"type":42},"2026-01-27",{"date":418,"type":21},"2026-01-30",{"date":420,"type":21},"2030-06-30",{"name":422,"class":49},"Shanghai Zhongshan Hospital",{"id":424,"slug":425,"hasResults":11,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":22,"phases":432,"briefSummary":433,"conditions":434,"keywords":436,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":446},"100586934","phase-1-a-first-in-human-study-using-bdc-4182-as-a-single-agent-in-advanced-gastric-and-gastroesophageal-cancer-100586934","NCT06921837","A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer","A Phase 1\u002F2, First-in-Human, Dose Escalation and Expansion Study of BDC-4182 as a Single Agent in Patients With Advanced Gastric and Gastroesophageal Cancer","Key Inclusion Criteria:\n\n* Has disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1.\n* Subjects must have histologically\u002Fcytologically confirmed gastric or gastroesophageal cancer that is metastatic (Stage 4) or unresectable (Stage 3).\n* Subjects must have received at least 1-2 prior lines of locally available standard therapies or must be intolerant of standard therapies.\n* For subjects in escalation: If prior Claudin 18 IHC expression is known, the subject must have some degree of Claudin 18 expression as defined as Positive or have expression ≥ 1% of tumor cells IHC ≥ 2+. Consult with Medical Monitor as needed.\n* Adequate organ function\n* Agree to have a biopsy prior to enrollment, at acceptable risk in the judgement of the Investigator. If a biopsy is not safely accessible or clinically feasible, an adequate archival tumor sample must be submitted.\n\nKey Exclusion Criteria:\n\n* Known central nervous system (CNS) metastases except for disease that is asymptomatic, clinically stable, and has not required steroids for at least 14 days before starting study treatment.\n* Cardiac disease, pulmonary disease, or hepatic disease\n* Active infection\n* History of inflammatory eye disease\n* Residual toxicity from a previous treatment\n* Any investigational agent or standard anti-cancer therapies within 28 days before starting study treatment or within 5 estimated elimination half-lives, whichever is shorter.",{"count":431,"type":21},122,[103,24],"A first-in-human study using BDC-4182 as a single agent in gastric and gastroesophageal cancers",[435,27],"Gastric Cancer Adenocarcinoma Metastatic",[336,437],"Gastroesophageal Cancer","2026-01-23",{"date":416,"type":42},{"date":441,"type":42},"2025-05-26",{"date":443,"type":21},"2029-05",{"name":445,"class":155},"Bolt Biotherapeutics, Inc.",16,{"id":448,"slug":449,"hasResults":11,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":186,"enrollmentInfo":454,"targetDuration":4,"studyType":22,"phases":456,"briefSummary":457,"conditions":458,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":468},"100575093","phase-2-a-clinical-trial-evaluating-tqb2102-for-injection-in-combination-with-behmosubaisumabpayamprolizumab-with-or-without-chemotherapy-in-unresectable-locally-advanced-recurrent-or-metastatic-human-epidermal-growth-factor-receptor-2-her2-positive-gastroesophageal-adenocarcinoma-100575093","NCT06767800","A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab\u002FPayamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma","Phase II Clinical Trial Evaluating the Efficacy and Safety of TQB2102 for Injection in Chemotherapy With Behmosubstituted Monoclonalb\u002FPembrolizumab ± Chemotherapy in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic HER2-Positive Gastroesophageal Adenocarcinoma","Inclusion Criteria:\n\n* 18 to 75 years of age, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, and life expectancy≥3 months;\n* Histopathologically confirmed unresectable locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma;\n* HER2 expression levels of Immunohistochemistry(IHC) 3+ or IHC 2+ and In Situ Hybridization (ISH) positivity were confirmed in tumor tissue;\n* Subject is able to provide previous compliant PD-L1 expression level test results or is able to provide sufficient and competent tumor tissue for PD-L1 expression level testing;\n* Patients who have not received prior systemic therapy for locally advanced or metastatic gastric cancer and who have experienced tumor recurrence or metastasis at least 6 months after the completion of prior adjuvant or neoadjuvant therapy may be enrolled;\n* Confirmation of at least one measurable lesion according to RECIST 1.1 criteria;\n* The main organs function well;\n* Male or female patient had no plans to become pregnant and voluntarily take effective contraceptive measures from agree with the study to at least 6 months after the last dose of study drug.\n\nExclusion Criteria:\n\n* Concurrent secondary malignancy. or other malignancy with no evidence of disease for more than 5 years;\n* Uncontrollable toxic reactions above CTC AE grade 1 due to any prior therapy, excluding alopecia;\n* Major surgical treatment, incisional biopsy or significant traumatic injury or prolonged unhealed wound or fracture within 28 days prior to first dose;\n* Prior history of interstitial lung disease\u002Fpneumonia (non-infectious) requiring steroidal drug intervention or current concomitant (or suspected) interstitial lung disease\u002Fpneumonia;\n* Arterial\u002Fvenous thrombotic events, such as cerebrovascular accidents, deep vein thrombosis, and pulmonary embolism, have occurred within 6 months prior to the first dose;\n* Individuals with a history of psychiatric drug abuse who are unable to quit or have mental disorders;\n* Subjects with the presence of any severe and\u002For uncontrolled disease；\n* Subjects who have received other antitumor drugs such as chemotherapy, radiotherapy, or immunotherapy within 4 weeks prior to the first dose, or who are still within the 5 half-life of the drug (whichever occurs shortest); have received a proprietary Chinese medicine with an antitumor indication as specified in the National Medical Products Administration(NMPA) -approved drug insert within 2 weeks prior to the first dose; and have experienced any hemorrhagic or bleeding event in the month prior to the initiation of study treatment ≥CTC Patients with AE grade 3;\n* Subjects with known Central nervous system (CNS) metastases and\u002For carcinomatous meningitis\n* Presence of severe bone damage and spinal cord compression due to tumor bone metastases;\n* History of live attenuated vaccination within 28 days prior to the first dose or planned live attenuated vaccination during the study;\n* History of severe hypersensitivity reactions to large molecule drugs or hypersensitivity to known components of TQB2102, benmelstobart or pembrolizumab for injection;\n* Active autoimmune disease requiring systemic therapy (e.g., use of disease-mitigating drugs, corticosteroids, or immunosuppressive agents) within 2 years prior to the first dose of medication\n* Diagnosis of immunodeficiency or undergoing systemic glucocorticoid therapy or any other form of immunosuppressive therapy that was continued within 2 weeks prior to initiation of study treatment.\n* Participants who have participated in and used other anti-tumor clinical trial drugs within 4 weeks before the first medication use\n* Unstable or serious concurrent medical conditions, as assessed by the Investigators, that would substantially increase the risk-benefit ratio of participating in the study.",{"count":455,"type":21},204,[24],"TQB2102 for injection is a novel antibody-coupled drug (ADC) that enhances binding to tumor cell surface HER2 proteins by simultaneously targeting the two non-overlapping epitopes of the HER2 protein, Endothelial Cell Dysfunction 2 (ECD2) and Endothelial Cell Dysfunction 4 (ECD4), increasing HER2 internalization, and then down-regulating the tumor cell surface HER2 proteins more effectively, and doubly blocking the HER2 signaling, to achieve the effects of trastuzumab and Pertuzumab alone and in combination. This is a Phase II study to evaluate the efficacy and safety of TQB2102 for injection in combination with Benmelstobart Injection \u002FPenpulimab Injection ± chemotherapy in patients with unresectable locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma",[27],"2025-07-28",{"date":461,"type":42},"2025-07-30",{"date":463,"type":42},"2024-11-21",{"date":465,"type":21},"2027-09",{"name":467,"class":155},"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.",39,{"id":470,"slug":471,"hasResults":11,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":476,"targetDuration":4,"studyType":22,"phases":477,"briefSummary":478,"conditions":479,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":92},"100591836","phase-2-adebrelimab-with-chemoradiotherapy-and-surgery-for-ggej-100591836","NCT06985602","Adebrelimab With Chemoradiotherapy and Surgery for G\u002FGEJ","Adebrelimab Combined With Chemoradiotherapy Followed by Surgery for Locally Advanced or Limited Metastatic Gastric\u002F Esophagogastric Junction Adenocarcinoma.","Inclusion Criteria:\n\n1. Pathologically confirmed esophagogastric junction (EGJ)\u002Fgastric adenocarcinoma.\n2. Patients with locally advanced disease (AJCC staging T4b or N2 fusion metastasis) or limited metastasis confirmed by endoscopy, CT, MRI, or PET\u002FCT scans, and multidisciplinary team (MDT) discussion.\n3. From a medical and surgical technical perspective, the primary lesion and surrounding abdominal lymph nodes are assessed as potentially resectable; limited metastatic lesions are evaluated by MDT for resectability or for the possibility of achieving curative treatment through other local treatment methods (such as local radiotherapy or radiofrequency ablation).\n4. Exclusion of peritoneal metastasis.\n5. Adequate hematological function: Neutrophil count ≥ 1.5 × 109\u002FL, Platelets ≥ 100 × 109\u002FL and Hemoglobin ≥90g\u002FL.\n6. Adequate liver function: Total bilirubin ≤ 1.5 × upper limit of normal (ULN); AST (SGOT) and ALT (SGPT) \\\u003C 2.5 × ULN in the absence of liver metastases, or \\\u003C 5 × ULN in case of liver metastases. ALP ≤ 2.5 × upper limit of normal (ULN); ALB ≥30g\u002FL.\n7. Adequate renal function: Serum creatinine ≤ 1.5 x ULN, and creatinine clearance ≥ 60 ml\u002Fmin.\n8. Adequate coagulation function: INR\u002FPT≤ 1.5 x ULN, aPTT≤ 1.5 x ULN.\n9. No serious concomitant disease that will threaten the survival of patients to less than 5 years.\n10. Male or female. Age ≥ 18 years and ≤80 years.\n11. Written (signed) informed consent.\n12. Good compliance with the study procedures, including lab and auxiliary examination and treatment.\n13. Female patients should not be pregnant or breast feeding.\n\nExclusion Criteria:\n\n1. Non-adenocarcinoma histology of gastric\u002Fesophagogastric junction tumors, such as squamous cell carcinoma or neuroendocrine carcinoma.\n2. The primary lesion is considered unresectable from a medical or surgical technical perspective.\n3. Imaging diagnosis indicates widespread metastasis (metastasis that does not meet the criteria for limited metastasis as defined above is considered widespread metastasis).\n4. Peripheral neuropathy of grade ≥2.\n5. Poor nutritional status, BMI \\\u003C18.5 kg\u002Fm², or PG-SGA score ≥9.\n6. Underwent major surgery or suffered a severe injury within 4 weeks prior to the first dose of the investigational drug.\n7. Presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.\n8. Received any investigational drug within 4 weeks prior to the first dose of the study drug.\n9. Required systemic treatment with corticosteroids (daily \\>10 mg prednisone equivalent) or other immunosuppressive agents within 2 weeks prior to the first dose of the investigational drug.\n10. Received an anti-tumor vaccine or live vaccine within 4 weeks before the first dose of the study drug.\n11. Diagnosed with any active autoimmune disease or a history of autoimmune diseases.\n12. History of immunodeficiency, including a positive HIV test, any acquired or congenital immunodeficiency diseases, or a history of organ transplantation or allogeneic bone marrow transplantation.\n13. Any condition within 14 days prior to treatment requiring systemic corticosteroid therapy (dose\\>10mg\u002Fday of prednisone or equivalent) or other immunosuppressive treatments.\n14. Presence of uncontrolled cardiac symptoms or conditions, such as:\n\n    * NYHA Class II or higher heart failure\n    * Unstable angina\n    * Myocardial infarction within the past year\n    * Clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention.\n15. Severe infection within 4 weeks prior to the first dose, including pneumonia requiring hospitalization, bacteremia, or infectious complications.\n16. History of interstitial lung disease, non-infectious pneumonia, pulmonary fibrosis, or other uncontrolled acute pulmonary diseases.\n17. Active pulmonary tuberculosis infection diagnosed by history or CT scan, or a history of active tuberculosis infection within the past year, or a history of untreated active tuberculosis infection more than one year ago.\n18. Active hepatitis B or hepatitis C.\n19. Laboratory abnormalities of sodium, potassium, or calcium greater than Grade 1 within 2 weeks before enrollment that cannot be corrected with treatment.\n20. Known allergy to monoclonal antibodies, any PD-1 components, paclitaxel, capecitabine, or any components used in their formulations.\n21. Pregnant or breastfeeding women, or women of childbearing potential who are unwilling or unable to use effective contraception.",{"count":409,"type":21},[24],"Gastric cancer is one of the most common and deadly cancers globally, characterized by a poor prognosis. Approximately 70% of patients are diagnosed at an advanced stage, and the 5-year survival rate is only around 10%. While advancements in targeted therapies and immunotherapy have improved treatment efficacy and extended survival, advanced gastric and gastroesophageal junction adenocarcinomas remain incurable. Subgroup analyses indicate that patients with limited metastases, such as liver oligometastasis or retroperitoneal lymph node metastasis, may benefit more from conversion therapy. However, current guidelines do not recommend specific treatment protocols for gastric cancer with limited metastasis. Immunotherapy has shown moderate efficacy in selected patients with advanced gastric adenocarcinoma. Additionally, low-dose radiotherapy (LDRT) may synergistically enhance antitumor responses when combined with immunotherapy. This Phase II trial aims to evaluate the safety and efficacy of combining Adebrelimab, chemotherapy, and LDRT before surgery in treating adult patients with gastric or gastroesophageal junction adenocarcinoma.",[27,67],"2025-05-15",{"date":482,"type":42},"2025-05-22",{"date":484,"type":21},"2025-05-16",{"date":486,"type":21},"2028-06-01",{"name":488,"class":49},"Jiangsu Cancer Institute & Hospital",{"id":490,"slug":491,"hasResults":11,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":186,"enrollmentInfo":497,"targetDuration":4,"studyType":22,"phases":499,"briefSummary":500,"conditions":501,"keywords":502,"overallStatus":210,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":4},"100515032","phase-1-the-sequential-combination-of-folfox-and-toripalimab-for-perioperative-immuno-oncology-therapy-of-her2-negative-adenocarcinoma-of-the-esophagogastric-junction-siewert-iii-100515032","NCT05986227","The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negative Adenocarcinoma of the Esophagogastric Junction (Siewert I\u002FII):","The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-oncology Therapy of HER2-negative Gastroesophageal Adenocarcinoma (Siewert I\u002FII): a Multicenter, Open-label, Randomized Controlled, Phase 1b\u002F2 Trial (SCORPIO\u002FNCCES05)","SCORPIO","Inclusion Criteria:\n\n* Age \\>\u002F= 18 years;\n* Male or Female;\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;\n* Histologically or cytologically confirmed locally advanced adenocarcinoma of esophagus or gastroesophageal junction (Siewert type I\u002FII);\n* Human epidermal growth factor receptor 2 (HER2)-negative tumors;\n* Clinical staging cT2-T4aNanyM0 or TanyN+M0 (UICC\u002FAJCC 8th edition), potentially resectable disease;\n* Adequate hematologic and end organ function based on laboratory results obtained within 14 days prior to initiation of study treatment;\n* For women of childbearing potential: agreement to remain abstinent；no evidence of pregnancy within 72 hours before the start of study regimen;\n* Must be willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Known unresectable disease，cT4b disease invading aorta or trachea;\n* Known distant metastases，including supraclavicular lymph nodal disease；\n* Uncontrollable pleural or pericardial effusion，or ascites requiring repeated interventions;\n* Prior chemotherapy, immunotherapy, targeted therapy, thoracic radiotherapy or prior surgical resection for an esophageal tumor;\n* Poor nutritional status, BMI \\\u003C 18.5 Kg\u002Fm2; if symptomatic nutritional support is corrected before randomization, enrollment may continue to be considered after assessment by the principal investigator;\n* History of allergy to biological drugs produced by Chinese hamster ovary cells, any component of toripalimab, tegafur, oxaliplatin or other platinum drugs;\n* History of severe allergic, allergic reactions, or other hypersensitivity to chimeric or humanized antibodies or fusion proteins;\n* Patients with prior malignancies are eligible if they have been disease-free for \\> 5 years and are deemed by their physician to be at low risk for recurrence. Patients with squamous or basal cell carcinoma of the skin, melanoma in situ, carcinoma in situ of the cervix, or carcinoma in situ of the colon or rectum that have been effectively treated are eligible, even if these conditions were diagnosed within 5 years prior to enrollment；\n* History of any active autoimmune disease or autoimmune disease, including myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid syndrome-related vascular thrombosis, Wegener's granulomatosis, Sjogren's syndrome, Guillain-Barre syndrome, multiple sclerosis, vasculitis, glomerulonephritis, etc.; hypothyroidism (hormone replacement therapy can be considered to be included);\n* History of immunosuppressive drugs, or systemic hormones used to achieve immunosuppressive purposes (dose \\> 10 mg\u002Fday prednisone or equivalent dose) within 2 weeks before the first use of the study drug; in the absence of active autoimmune diseases, inhaled or local steroids are allowed and doses \\> 10 mg\u002Fday prednisone or equivalent doses of adrenocorticotropic hormone replacement;\n* History of type 1 diabetes, whose blood glucose is controlled after treatment with a stable dose of insulin dosing regimen may be enrolled in this study;\n* History of live attenuated vaccines are received within 4 weeks before the first use of the study drug;\n* History of major surgery or severe trauma within 4 weeks before the first use of the study drug;\n* History of eczema, psoriasis, lichen simplex chronicus, or dermatologic manifestations of vitiligo (eg, patients with psoriatic arthritis were excluded from the study) were permitted to enroll in this study if they met the following conditions: a) had rash coverage less than 10% of body surface area (BSA); b) had adequately controlled disease at baseline and required only low-potency topical steroid therapy; c) did not have an acute exacerbation of the underlying disease within the past 12 months without the need for PUVA (psoralen plus ultraviolet A radiation), methotrexate, retinoids, biologics, oral calcineurin inhibitors, high-titer, or oral steroid therapy for\\]；\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (such as bronchiolitis obliterans), drug-induced pneumonia, idiopathic pneumonia, interstitial pneumonia, or evidence of active pneumonia on screening chest CT scan;\n* History of immunodeficiency, including HIV test positive, or suffering from other acquired or congenital immunodeficiency diseases, or a history of organ transplantation or allogeneic bone marrow transplantation;\n* Uncontrolled cardiac clinical symptoms or diseases, including but not limited to: a) NYHA class II or higher heart failure; b) unstable angina; c) myocardial infarction within 1 year; d) clinically significant supraventricular or ventricular arrhythmia that remains poorly controlled without or after clinical intervention.\n* Known hereditary or acquired bleeding and thrombophilia (such as hemophilia, coagulation dysfunction, thrombocytopenia, etc.);\n* Known serious infection (CTCAE \\> 2) within 4 weeks before the first use of the study drug, such as severe pneumonia requiring hospitalization, bacteremia, infectious complications, etc.; baseline chest imaging showed active pulmonary inflammation, symptoms and signs of infection within 14 days before the first use of the study drug or oral or intravenous antibiotics, except for the prophylactic use of antibiotics;\n* Active pulmonary tuberculosis infection detected by medical history or CT examination, or history of active pulmonary tuberculosis infection within 1 year before enrollment, or history of active pulmonary tuberculosis infection more than 1 year ago but without regular treatment;\n* Active hepatitis B (HBV DNA ≥ 2000 IU\u002FmL or 104 copies\u002FmL), hepatitis C (hepatitis C antibody positive, and HCV RNA above the lower limit of detection of the analytical method);\n* Pregnant or lactating women;\n* Other factors that may lead to forced halfway termination of the study as judged by the investigator, such as having other serious diseases (including mental illness) requiring concomitant treatment, alcoholism, drug abuse, family or social factors that may affect the safety or compliance of the subject.",{"count":498,"type":21},126,[103,24],"The addition of immunotherapy to chemotherapy improves outcomes in patients with HER2-negative gastroesophageal adenocarcinoma (GEA), and investigators aim to explore its role in the perioperative setting. Moreover, optimizing the timing schedule of these two therapies is critical when balancing efficacy and safety. This Chinese, multicenter, open-label phase 1b\u002F2 trial will evaluate the efficacy and toxicity of perioperative folinic acid, fluoro-uracil, oxali-platin (FOLFOX), and toripalimab (JS001, a novel PD-1 inhibitor) in combination at various schedules in the neoadjuvant setting in patients with HER2-negative resectable GEA: three cycles each in Arm A: FOLFOX (D1, q2w) followed by toripalimab (D3, 3 mg\u002Fkg, q2w); Arm B: concurrent FOLFOX (D1, q2w) combined with toripalimab (D1, 3 mg\u002Fkg, q2w); Arm C: toripalimab (D1, 3 mg\u002Fkg, q2w) followed by FOLFOX (D3, q2w); Arm D: FOLFOX (D1, q2w) alone. The primary end-point is the dose-limiting toxicity in Phase 1b and the pathological complete response rate in Phase 2; secondary end-points include major pathologic response, disease-free survival, and event-free survival.A fixed sample size of 126 patients is used in this study, with a safety run-in period (n = 6) and cohort expansion period (n = 24), a dropout rate of 5% within 12 months of follow-up. Each arm receives three cycles of FOLFOX (D1, q2w) followed by 15 cycles of toripalimab (D1, 240 mg, q3w) in the neoadjuvant setting. Pre-treatment biopsies, post-resection specimens, serial liquid biopsy, and gut microbiota samples on treatment will be collected to explore the biomarkers' predictive value on diverse schedule efficacy and safety.",[27],[33],"2023-08-03",{"date":505,"type":42},"2023-08-14",{"date":507,"type":21},"2023-08-01",{"date":509,"type":21},"2026-07-01",{"name":511,"class":49},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"]